

Mario Humberto Cardiel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3703626/publications.pdf>

Version: 2024-02-01

81
papers

8,105
citations

147801
31
h-index

69250
77
g-index

86
all docs

86
docs citations

86
times ranked

8744
citing authors

#	ARTICLE	IF	CITATIONS
1	A Critical Analysis of the First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e312-e316.	0.9	0
2	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. <i>Rheumatology International</i> , 2022, 42, 41-49.	3.0	18
3	Controversies in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e651-e658.	0.9	1
4	Can presence of HLA type I and II alleles be associated with clinical spectrum of CHIKV infection?. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	3.0	0
5	Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 215-228.	0.3	2
6	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. <i>Lupus</i> , 2021, 30, 630-640.	1.6	2
7	Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. <i>Clinical Rheumatology</i> , 2021, 40, 2913-2920.	2.2	22
8	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020, 59, e165-e168.	1.9	0
9	Demographic and clinical characteristics of chikungunya patients from six Colombian cities, 2014-2015. <i>Emerging Microbes and Infections</i> , 2019, 8, 1490-1500.	6.5	17
10	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. <i>Clinical Rheumatology</i> , 2019, 38, 2737-2746.	2.2	10
11	Response to: "Clinical evidence guidelines in systemic lupus erythematosus: revaluation" by Scheinberg. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e120-e120.	0.9	1
12	A Consensus Position Paper From REAL-PANLAR Group About the Methodological Approach for the Accreditation Process of Centers of Excellence in Rheumatoid Arthritis in Latin America. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 54-58.	0.9	7
13	Starting biologic therapy in rheumatoid arthritis. A Colombian experience. <i>Revista Colombiana De Reumatología</i> , 2018, 25, 1-2.	0.1	0
14	Prevalencia de manifestaciones musculoesqueléticas y discapacidad asociada en una población urbana habitante a gran altura. Estudio COPCORD. Estadio I. <i>Reumatología Clínica</i> , 2018, 14, 278-284.	0.5	16
15	Therapeutic Guidelines for Latin American Lupus Patients. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 41-44.	0.9	7
16	Starting biologic therapy in rheumatoid arthritis. A Colombian experience. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2018, 25, 1-2.	0.0	0
17	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del</i>) Tj ETQq1 1 0.784314 rgBT _{0.9} /Overlock Diseases, 2018, 77, 1549-1557.	0.9	96
18	Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 932-942.	5.6	78

#	ARTICLE	IF	CITATIONS
19	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
20	Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 193-199.	0.9	13
21	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2071-2074.	0.9	89
22	Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries. <i>Clinical Rheumatology</i> , 2017, 36, 2789-2797.	2.2	14
23	Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients. <i>Archivos De Cardiología De Mexico</i> , 2016, 86, 297-304.	0.2	4
24	Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. <i>Arthritis and Rheumatology</i> , 2016, 68, 932-943.	5.6	138
25	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1133-1138.	0.9	186
26	Prevalence of musculoskeletal disorders and rheumatic diseases in Cuenca, Ecuador: a WHO-ILAR COPCORD study. <i>Rheumatology International</i> , 2016, 36, 1195-1204.	3.0	33
27	Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain. <i>Reumatología Clínica (English Edition)</i> , 2016, 12, 256-262.	0.3	0
28	Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain. <i>Reumatología Clínica</i> , 2016, 12, 256-262.	0.5	23
29	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
30	The Social Gap Index and the prevalence of osteoarthritis in the community: a cross-sectional multilevel study in Mexico. <i>Clinical Rheumatology</i> , 2016, 35, 175-182.	2.2	13
31	REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 175-180.	0.9	25
32	Association of Regional and Cultural Factors With the Prevalence of Rheumatoid Arthritis in the Mexican Population. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 57-62.	0.9	18
33	Burden of illness of rheumatoid arthritis in Latin America: a regional perspective. <i>Clinical Rheumatology</i> , 2015, 34, 9-15.	2.2	14
34	Rheumatoid arthritis in Latin America. Important challenges to be solved. <i>Clinical Rheumatology</i> , 2015, 34, 1-3.	2.2	20
35	Calidad de vida relacionada con la salud en artritis reumatoide, osteoartritis, diabetes mellitus, insuficiencia renal terminal y población geriátrica. Experiencia de un Hospital General en México. <i>Reumatología Clínica</i> , 2015, 11, 68-72.	0.5	29
36	Health Related Quality of Life in Rheumatoid Arthritis, Osteoarthritis, Diabetes Mellitus, End Stage Renal Disease and Geriatric Subjects. Experience From a General Hospital in Mexico. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 68-72.	0.3	11

#	ARTICLE	IF	CITATIONS
37	ActualizaciÃ³n de la GuÃa Mexicana para el Tratamiento FarmacolÃ³gico de la Artritis Reumatoide del Colegio Mexicano de ReumatologÃa. <i>ReumatologÃa ClÃnica</i> , 2014, 10, 227-240.	0.5	44
38	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2014, 10, 152-159.	0.3	0
39	Update of the Mexican College of Rheumatology Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2014, 10, 227-240.	0.3	14
40	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>ReumatologÃa ClÃnica</i> , 2014, 10, 152-159.	0.5	22
41	Estrategia Â“treat to targetÂ” en la artritis reumatoide: beneficios reales. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 101-105.	0.5	22
42	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 106-112.	0.5	50
43	Treat to Target Strategy in Rheumatoid Arthritis: Real Benefits. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2013, 9, 101-105.	0.3	9
44	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>ReumatologÃa ClÃnica (English)</i> Tj ETQq0 0.0 rgBT /Overlock 10	0.3	
45	A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R164.	3.5	100
46	Treating rheumatoid arthritis in Latin America: current challenges and future treatment strategies. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 139-142.	0.3	3
47	Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indianâ€“European populations. <i>Arthritis and Rheumatism</i> , 2012, 64, 3687-3694.	6.7	70
48	Enfermedad de Cushing como causa de osteoporosis grave. Un reto clÃnico. <i>ReumatologÃa ClÃnica</i> , 2012, 8, 278-279.	0.5	6
49	Cushings Disease as a Cause of Severe Osteoporosis: A Clinical Challenge. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2012, 8, 278-279.	0.3	2
50	Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline. <i>Arthritis Care and Research</i> , 2012, 64, 1135-1143.	3.4	65
51	Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. <i>Journal of rheumatology Supplement</i> , The, 2011, 86, 3-8.	2.2	200
52	Present and Future of Rheumatic Diseases in Latin America. Are We Prepared to Face Them?. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2011, 7, 279-280.	0.3	6
53	Geographical factors in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 259-261.	0.3	2
54	Reaching those most in need: A scoping review of interventions to improve health care quality for disadvantaged populations with osteoarthritis. <i>Arthritis Care and Research</i> , 2011, 63, 39-52.	3.4	39

#	ARTICLE	IF	CITATIONS
55	Towards Elucidation of the Epidemiology of the Rheumatic Diseases in Mexico. COPCORD Studies in the Community. <i>Journal of rheumatology Supplement</i> , The, 2011, 86, 1-2.	2.2	13
56	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
57	A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R192.	3.5	23
58	Management of Patients With Rheumatoid Arthritis in Latin America. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 203-210.	0.9	44
59	Community-Based Study to Estimate Prevalence and Burden of Illness of Rheumatic Diseases in Cuba: A COPCORD Study. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 51-55.	0.9	77
60	Prevalence of Antinuclear Antibodies in 3 Groups of Healthy Individuals. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 325-329.	0.9	81
61	Cultural adaptation and validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) in a Mexican population. <i>Clinical Rheumatology</i> , 2008, 27, 151-161.	2.2	15
62	Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 2470-2480.	6.7	131
63	Challenges in the management of rheumatoid arthritis in developing countries. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 621-641.	3.3	70
64	Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 267-269.	3.0	2
65	Clinical Utility of Specialized Immunologic Testing in Rheumatology in a Secondary Level Hospital in Mexico. <i>Reumatología Clínica (English Edition)</i> , 2007, 3, 110-116.	0.3	1
66	Tumor Necrosis Factor- α Promoter Polymorphisms in Mexican Patients With Spondyloarthritis. <i>Human Immunology</i> , 2006, 67, 826-832.	2.4	36
67	Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. <i>Arthritis and Rheumatism</i> , 2005, 52, 1138-1147.	6.7	347
68	Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 77-88.	4.1	14
69	Tumor necrosis factor-alpha α 308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. <i>Journal of Autoimmunity</i> , 2005, 24, 63-68.	6.5	53
70	The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2004, 83, 1-17.	1.0	372
71	Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. <i>Human Immunology</i> , 2004, 65, 1437-1442.	2.4	29
72	LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2003, 48, 442-454.	6.7	222

#	ARTICLE	IF	CITATIONS
73	Risk Factors Associated with Depression in Patients with Type 2 Diabetes Mellitus. Archives of Medical Research, 2002, 33, 53-60.	3.3	86
74	Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis and Rheumatism, 2002, 47, 242-248.	6.7	82
75	Cross-cultural equivalence of a brief helplessness scale for Spanish-speaking rheumatology patients in the United States. Arthritis and Rheumatism, 1999, 42, 341-350.	6.7	11
76	Omega-3 fatty acids in rheumatoid arthritis: an overview. Seminars in Arthritis and Rheumatism, 1998, 27, 366-370.	3.4	69
77	Measurement of depression in mexican patients with rheumatoid arthritis: Validity of the beck depression inventory. Arthritis and Rheumatism, 1997, 10, 194-199.	6.7	40
78	Factors associated with mortality in systemic lupus erythematosus (SLE). A nested case-control study. Journal of Clinical Epidemiology, 1997, 50, S3.	5.0	0
79	Validity of retrospective disease activity assessment in systemic lupus erythematosus. Journal of Clinical Epidemiology, 1996, 49, S3.	5.0	1
80	Systemic Lupus Erythematosus in Males A Study of 107 Latin American Patients. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 507		
81	Comparative Effectiveness of Packages of Treatment Including Ultrasound or Transcutaneous Electrical Nerve Stimulation in Painful Shoulder Syndrome. Physiotherapy, 1993, 79, 251-253.	0.4	33